Ascletis Pharma Inc (1672.HK)

Name: Ascletis Pharma Inc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2026-04-07

Latest Quarter

2026-04-07

Revenue

$1.1M

Net Income

-$88.0M

Operating Margin

-17,575.7%

Free Cash Flow

-$344M

Debt / Assets

7.5%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Ascletis Pharma Inc (1672.HK).
Income Statement (Quarterly)	2026-04-07	2025-06-30	2025-03-31	2024-12-31
Revenue	1,081,000	1,081,000	540,500	1,283,000
Cost of Revenue	960,000	960,000	480,000	548,000
Gross Profit	121,000	121,000	60,500	735,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	43,302,000	43,302,000	21,651,000	60,388,000
Operating Expenses	190,114,000	190,114,000	95,057,000	296,154,000
Operating Income	-189,993,000	-189,993,000	-94,996,500	-295,419,000
Interest Expense	0	0	0	0
Income Before Tax	-87,951,000	-87,951,000	-43,975,500	-170,618,000
Income Tax Expense	0	0	0	0
Net Income	-87,951,000	-87,951,000	-43,975,500	-170,618,000
Per Share
EPS	-0.09	-0.09	-0.05	-0.17
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Ascletis Pharma Inc (1672.HK).
Income Statement (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Revenue	1,283,000	56,596,000	54,090,000	76,876,000	35,001,000
Cost of Revenue	548,000	30,606,000	78,782,000	37,703,000	58,498,000
Gross Profit	735,000	25,990,000	-24,692,000	39,173,000	-23,497,000
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	101,744,000	62,963,000	32,414,000	37,363,000	47,793,000
Operating Expenses	296,154,000	326,198,000	314,937,000	223,256,000	129,439,000
Operating Income	-295,419,000	-306,811,000	-262,817,000	-184,083,000	-152,936,000
Interest Expense	0	144,000	157,000	125,000	135,000
Income Before Tax	-300,936,000	-144,715,000	-314,843,000	-199,017,000	-209,241,000
Income Tax Expense	0	0	51,869,000	0	0
Net Income	-300,936,000	-144,715,000	-366,712,000	-199,017,000	-209,241,000
Per Share
EPS	-0.30	-0.13	-0.34	-0.19	-0.20
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Ascletis Pharma Inc (1672.HK).
Balance Sheet (Quarterly)	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Assets
Cash and Cash Equivalents	865,730,000	330,117,000	2,470,834,000	2,495,496,000
Short Term Investments	1,081,801,000	1,969,286,000	11,200,000	5,200,000
Net Receivables	152,000	4,005,000	23,873,000	0
Inventory	4,373,000	6,071,000	20,519,000	56,233,000
Total Current Assets	1,970,782,000	2,332,756,000	2,544,726,000	2,631,551,000
Property Plant Equipment	57,074,000	68,277,000	73,041,000	77,509,000
Goodwill and Intangibles	12,118,000	26,315,000	16,559,000	0
Total Assets	2,124,572,000	2,491,009,000	2,657,042,000	2,829,959,000
Liabilities
Account Payables	31,000	649,000	3,135,000	1,054,000
Short Term Debt	6,246,000	5,710,000	2,416,000	1,568,000
Total Current Liabilities	153,053,000	140,679,000	108,189,000	90,971,000
Long Term Debt	1,387,000	2,706,000	1,821,000	1,182,000
Total Liabilities	158,410,000	148,943,000	117,156,000	100,887,000
Shareholders Equity
Retained Earnings	-1,475,339,000	-1,174,403,000	-1,029,688,000	0
Total Shareholders Equity	1,966,162,000	2,342,066,000	2,539,886,000	2,729,072,000

Balance sheet annual history for Ascletis Pharma Inc (1672.HK).
Balance Sheet (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Assets
Cash and Cash Equivalents	865,730,000	330,117,000	2,470,834,000	2,495,496,000	2,714,011,000
Short Term Investments	1,081,801,000	1,969,286,000	11,200,000	5,200,000	0
Net Receivables	152,000	4,005,000	23,873,000	0	0
Inventory	4,373,000	6,071,000	20,519,000	56,233,000	58,894,000
Total Current Assets	1,970,782,000	2,332,756,000	2,544,726,000	2,631,551,000	2,829,987,000
Property Plant Equipment	57,074,000	68,277,000	73,041,000	77,509,000	84,579,000
Goodwill and Intangibles	12,118,000	26,315,000	16,559,000	0	90,702,000
Total Assets	2,124,572,000	2,491,009,000	2,657,042,000	2,829,959,000	3,067,072,000
Liabilities
Account Payables	31,000	649,000	3,135,000	1,054,000	930,000
Short Term Debt	6,246,000	5,710,000	2,416,000	1,568,000	1,144,000
Total Current Liabilities	153,053,000	140,679,000	108,189,000	90,971,000	73,772,000
Long Term Debt	1,387,000	2,706,000	1,821,000	1,182,000	443,000
Total Liabilities	158,410,000	148,943,000	117,156,000	100,887,000	85,422,000
Shareholders Equity
Retained Earnings	-1,475,339,000	-1,174,403,000	-1,029,688,000	0	0
Total Shareholders Equity	1,966,162,000	2,342,066,000	2,539,886,000	2,729,072,000	2,981,650,000

Cash flow quarterly history for Ascletis Pharma Inc (1672.HK).
Cash Flow Statement (Quarterly)	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Operating Activities
Net Income	-300,936,000	-144,715,000	-314,843,000	-199,017,000
Depreciation & Amortization	20,454,000	18,480,000	30,191,000	29,545,000
Stock Based Compensation	3,003,000	1,331,000	3,193,000	7,130,000
Change in Working Capital	13,787,000	38,526,000	33,807,000	-10,175,000
Operating Cash Flow	-341,579,000	-144,162,000	-142,453,000	-146,930,000
Investing Activities
Capital Expenditure	-2,148,000	-19,158,000	-14,401,000	-7,198,000
Investments	-2,095,000	-6,213,000	-14,401,000	-4,968,000
Investing Cash Flow	978,906,000	149,845,000	-1,297,387,000	-274,492,000
Financing Activities
Debt Repayment	-4,733,000	-2,391,000	-2,223,000	0
Common Stock Issued/Repurchased	-98,531,000	-78,961,000	961,000	-28,689,000
Dividends Paid	0	0	0	0
Financing Cash Flow	-103,508,000	-81,496,000	-1,419,000	-31,098,000
Summary
Free Cash Flow	-343,727,000	-163,320,000	-156,854,000	-154,128,000
Net Change in Cash	534,209,000	-73,651,000	-1,323,643,000	-483,093,000

Cash flow annual history for Ascletis Pharma Inc (1672.HK).
Cash Flow Statement (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Operating Activities
Net Income	-300,936,000	-144,715,000	-314,843,000	-199,017,000	-209,241,000
Depreciation & Amortization	20,454,000	18,480,000	30,191,000	29,545,000	27,163,000
Stock Based Compensation	3,003,000	1,331,000	3,193,000	7,130,000	4,612,000
Change in Working Capital	13,787,000	38,526,000	33,807,000	-10,175,000	10,426,000
Operating Cash Flow	-341,579,000	-144,162,000	-142,453,000	-146,930,000	-84,911,000
Investing Activities
Capital Expenditure	-2,148,000	-19,158,000	-14,401,000	-7,198,000	-38,960,000
Investments	-2,095,000	-6,213,000	-14,401,000	-4,968,000	-4,922,000
Investing Cash Flow	978,906,000	149,845,000	-1,297,387,000	-274,492,000	132,297,000
Financing Activities
Debt Repayment	-4,733,000	-2,391,000	-2,223,000	0	0
Common Stock Issued/Repurchased	-98,531,000	-78,961,000	961,000	-28,689,000	-19,601,000
Dividends Paid	0	0	0	0	0
Financing Cash Flow	-103,508,000	-81,496,000	-1,419,000	-31,098,000	-21,670,000
Summary
Free Cash Flow	-343,727,000	-163,320,000	-156,854,000	-154,128,000	-123,871,000
Net Change in Cash	534,209,000	-73,651,000	-1,323,643,000	-483,093,000	-84,540,000